The developmental component of the UCSD CFAR is designed to facilitate and encourage new investigators and new ideas in HIV/AIDS research. The intent is to optimize opportunities for productive research by providing immediate financial support in association with resource support provided by the Core facilities. Four categories of developmental grants will be supported, although the number and type of these categories are flexible: (1) junior faculty and investigators new to AIDS research;(2) feasibility studies, (3) evolving research opportunities;and (4) newly recruited faculty. These grants will enable new faculty members with a background or an interest in HIV/AIDS research to receive immediate funding for a project while encouraging new collaborations and support within the CFAR and the University. Requests for submission of developmental grants are advertised through the Administrative Core twice a year for funding in January and June. Faculty at all four CFAR member institutions are eligible to apply. The submissions are evaluated by an expert review committee, and additional ad hoc reviewers from related fields are added as needed. Merit is the driving criterion for making the awards;however, fostering the development of junior and minority investigators are two important programmatic goals that are also considered in prioritization of awards. The maximum amount for the awards currently given is $50,000 for unfunded junior investigators and $30,000 for others. As part of their award, investigators are required to provide documentation of publications and peer-reviewed funding that result from the developmental awards. They are also required to cite CFAR developmental funds in publications resulting from work supported by developmental grants. With the growth of the CFAR and the recent addition of The Scripps Research Institute as a member institution, we anticipate a greater number of innovative and timely projects will be funded, attracting new members and affiliates who can advance HIV and AIDS research.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036214-17
Application #
8080823
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2010-06-01
Budget End
2011-05-31
Support Year
17
Fiscal Year
2010
Total Cost
$457,478
Indirect Cost
Name
University of California San Diego
Department
Type
DUNS #
804355790
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Naticchia, Matthew R; Laubach, Logan K; Tota, Ember M et al. (2018) Embryonic Stem Cell Engineering with a Glycomimetic FGF2/BMP4 Co-Receptor Drives Mesodermal Differentiation in a Three-Dimensional Culture. ACS Chem Biol 13:2880-2887
Blumenthal, Jill; Jain, Sonia; Mulvihill, Evan et al. (2018) Perceived versus calculated HIV risk: Implications for Pre-exposure prophylaxis uptake in a randomized trial of men who have sex with men. J Acquir Immune Defic Syndr :
Kardava, Lela; Sohn, Haewon; Youn, Christine et al. (2018) IgG3 regulates tissue-like memory B cells in HIV-infected individuals. Nat Immunol 19:1001-1012
Wagner, Karla D; Syvertsen, Jennifer L; Verdugo, Silvia R et al. (2018) A mixed methods study of the social support networks of female sex workers and their primary noncommercial male partners in Tijuana, Mexico. J Mix Methods Res 12:437-457
Bastos, Francisco I; Bastos, Leonardo Soares; Coutinho, Carolina et al. (2018) HIV, HCV, HBV, and syphilis among transgender women from Brazil: Assessing different methods to adjust infection rates of a hard-to-reach, sparse population. Medicine (Baltimore) 97:S16-S24
Cepeda, Javier A; Eritsyan, Ksenia; Vickerman, Peter et al. (2018) Potential impact of implementing and scaling up harm reduction and antiretroviral therapy on HIV prevalence and mortality and overdose deaths among people who inject drugs in two Russian cities: a modelling study. Lancet HIV 5:e578-e587
Namazi, Golnaz; Fajnzylber, Jesse M; Aga, Evgenia et al. (2018) The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. J Infect Dis 218:1954-1963
Lada, Steven M; Huang, Karissa; VanBelzen, D Jake et al. (2018) Quantitation of Integrated HIV Provirus by Pulsed-Field Gel Electrophoresis and Droplet Digital PCR. J Clin Microbiol 56:
Huang, Mia L; Michalak, Austen L; Fisher, Christopher J et al. (2018) Small Molecule Antagonist of Cell Surface Glycosaminoglycans Restricts Mouse Embryonic Stem Cells in a Pluripotent State. Stem Cells 36:45-54
Skaathun, Britt; Voisin, Dexter R; Cornwell, Benjamin et al. (2018) A Longitudinal Examination of Factors Associated with Network Bridging Among YMSM: Implications for HIV Prevention. AIDS Behav :

Showing the most recent 10 out of 921 publications